Evidence map›Paper›PMID 29305606›Full record

ArticleInvestigative ophthalmology & visual science2018

Xanthohumol Protects Morphology and Function in a Mouse Model of Retinal Degeneration.

Nathaniel F Henneman, Stephanie L Foster, Micah A Chrenek, Jana T Sellers, Charles B Wright, Robin H Schmidt, John M Nickerson, Jeffrey H Boatright

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nathaniel F HennemanDepartment of Ophthalmology, School of Medicine, Emory University, Atlanta, Georgia, United States.
Stephanie L FosterDepartment of Human Genetics, School of Medicine, Emory University, Atlanta, Georgia, United States.
Micah A ChrenekDepartment of Ophthalmology, School of Medicine, Emory University, Atlanta, Georgia, United States.
Jana T SellersDepartment of Ophthalmology, School of Medicine, Emory University, Atlanta, Georgia, United States.
Charles B WrightDepartment of Ophthalmology, School of Medicine, Emory University, Atlanta, Georgia, United States.
Robin H SchmidtDepartment of Ophthalmology, School of Medicine, Emory University, Atlanta, Georgia, United States.
John M NickersonDepartment of Ophthalmology, School of Medicine, Emory University, Atlanta, Georgia, United States.
Jeffrey H BoatrightDepartment of Ophthalmology, School of Medicine, Emory University, Atlanta, Georgia, United States.
Emory University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI GEISERT, ELDON E · 1986 to 2025
$15.3M
VIsion Science Training in AtlantaT32EY007092 · NEI · EMORY UNIVERSITY · PI Machelle T. Pardue · 1985 to 2026
$4.6M
Oligonucleotide Repair of a Retinal Degeneration ModelR01EY014026 · NEI · EMORY UNIVERSITY · PI BOATRIGHT, JEFFREY H · 2004 to 2015
$4.1M
Ocular Growth, Emmetropia, and Interphotoreceptor Retinoid-Binding Protein (IRBP)R01EY021592 · NEI · EMORY UNIVERSITY · PI BOATRIGHT, JEFFREY H, IUVONE, P MICHAEL · 2013 to 2021
$3.3M
Gene Delivery in Retinal DiseasesR01EY016470 · NEI · EMORY UNIVERSITY · PI NICKERSON, JOHN M · 2006 to 2015
$3.2M
Deciphering the Usher I protein interactome using a genetic approachR01DC009246 · NIDCD · CASE WESTERN RESERVE UNIVERSITY · PI ZHENG, QING Y · 2009 to 2013
$1.6M
Bridging animal and human models of exercise-induced visual rehabilitationI21RX001924 · VA · VETERANS HEALTH ADMINISTRATION · PI BOATRIGHT, JEFFREY H · 2015 to 2017
–
NEI NIH HHS P30 EY006360NEI NIH HHS R01 EY014026NEI NIH HHS R01 EY016470NEI NIH HHS R01 EY021592NEI NIH HHS T32 EY007092NIDCD NIH HHS R01 DC009246NIGMS NIH HHS T32 GM008169RRD VA I21 RX001924
6 · The paper itself

Abstract

Purpose: To investigate whether treatment with xanthohumol (XN), the principal prenylated chalconoid from Humulus lupulus (hops), is protective in a mouse model of light-induced retinal degeneration (LIRD). Methods: Mice (129S2/SvPasCrl) were intraperitoneally injected with vehicle or XN prior to toxic light exposure and every 3 days thereafter. Retinal function was assessed by electroretinograms at 1, 2, and 4 weeks following toxic light exposure. Visual acuity was tested by optokinetic tracking 1 week and 4 weeks after toxic light exposure. Retina sections were stained with hematoxylin and eosin for morphologic analysis or by TUNEL. Redox potentials were assessed in retinal tissue by measuring levels of cysteine (CYS), cystine (CYSS), glutathione (GSH), and glutathione disulfide (GSSG) using HPLC with fluorescence detection. Results: Toxic light significantly suppressed retinal function and visual acuity, severely disrupted the photoreceptor cell layer, and significantly decreased the number of nuclei and increased the accumulation of TUNEL-labeled cells in the outer nuclear layer. These effects were prevented by XN treatment. Treatment with XN also maintained GSSG and CYSS redox potentials and the total CYS pool in retinas of mice undergoing toxic light exposure. Conclusions: XN treatment partially preserved visual acuity and retinal function in the LIRD mouse. Preservation of retinal CYS and of GSSG and CYSS redox potentials may indicate that XN treatment induces an increased antioxidant response, but further experiments are needed to verify this potential mechanism. To our knowledge, this is the first study to report protective effects of XN in a model of retinal degeneration.

Indexed as

Oxidative StressAnimalsDisease Models, AnimalElectroretinographyFlavonoidsInjections, IntraperitonealMaleMicePropiophenonesRetinaRetinal DegenerationFlavonoidsPropiophenonesxanthohumol

Identifiers

PMID29305606
PMCPMC5756043
OpenAlexW2781929927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.